SCHEMBL4086435

SCHEMBL4086435

CCCCOc1ccc(NC(=O)NC(Cc2ccccc2OC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)s2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 2/20 0.40
NPSR1 Q6W5P4 1/20 0.39
TAOK1 Q7L7X3 1/20 0.39
TAOK3 Q9H2K8 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
EPHX2 P34913 3/20 0.38
S1PR1 P21453 1/20 0.38
S1PR3 Q99500 1/20 0.38
PPARA Q07869 2/20 0.38
FPR2 P25090 1/20 0.38
ADCY6 O43306 1/20 0.37
ADCY3 O60266 1/20 0.37
ADCY9 O60503 1/20 0.37
ADCY5 O95622 1/20 0.37
ADCY8 P40145 1/20 0.37
ADCY7 P51828 1/20 0.37
ADCY2 Q08462 1/20 0.37
ADCY1 Q08828 1/20 0.37
ADCY4 Q8NFM4 1/20 0.37
FAAH O00519 6/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090974 0.87 EPHX1 (0.40) GCGREPHX2FPR2ADCY6ADCY3
SCHEMBL4097815 0.86 GCGR (0.39) GCGREPHX2FPR2ADCY6ADCY3
SCHEMBL4091740 0.81 GCGR (0.46) GCGRTAOK1TAOK3S1PR1S1PR3
SCHEMBL2663017 0.79 GCGR (0.45) GCGRNPSR1FFAR4EPHX2S1PR1
SCHEMBL4091865 0.77 GCGR (0.49) GCGREPHX2S1PR1ADCY6ADCY3
SCHEMBL4095297 0.72 GCG (0.49) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4085327 0.72 GCGR (0.57) GCGREPHX2ADCY6ADCY3ADCY9
SCHEMBL4091687 0.71 GCGR (0.47) GCGREPHX2ADCY6ADCY3ADCY9
SCHEMBL6188310 0.70 FPR2 (0.43) GCGREPHX2FPR2ADCY6ADCY3
SCHEMBL4085217 0.69 GCGR (0.54) GCGREPHX2PPARAADCY6ADCY3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885NPSR1 440/4885TAOK1 1132/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885NPSR1 440/4885TAOK1 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.